<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639714</url>
  </required_header>
  <id_info>
    <org_study_id>GO-004</org_study_id>
    <nct_id>NCT03639714</nct_id>
  </id_info>
  <brief_title>A Study of a Personalized Neoantigen Cancer Vaccine</brief_title>
  <official_title>An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gritstone Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gritstone Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical&#xD;
      activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination&#xD;
      with nivolumab and ipilimumab, in patients with metastatic non-small cell lung cancer,&#xD;
      microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma, and metastatic&#xD;
      urothelial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tumors harboring non-synonymous deoxyribonucleic acid (DNA) mutations can present peptides&#xD;
      containing these mutations as non-self antigens in the context of HLA on the tumor cell&#xD;
      surface. A fraction of mutated peptides result in neoantigens capable of generating T-cell&#xD;
      responses that exclusively target tumor cells. Sensitive detection of these mutations allows&#xD;
      for the identification of neoantigens unique to each patient's tumor to be included in a&#xD;
      personalized cancer vaccine that targets these neoantigens. This vaccine regimen uses two&#xD;
      vaccine vectors as a heterologous prime/boost approach (GRT-C901 first followed by GRT-R902)&#xD;
      to stimulate an immune response. This study will explore the safety and early clinical&#xD;
      activity of this patient-specific immunotherapy intended to induce T-cell responses specific&#xD;
      for neoantigens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 13, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)</measure>
    <time_frame>Initiation of study treatment through 100 days post-last dose (up to approximately 27 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) in Phase 2 using RECIST v1.1</measure>
    <time_frame>Initiation of study treatment until disease progression (up to approximately 27 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify the recommended Phase 2 dose (RP2D) of GRT-C901 and GRT-R902</measure>
    <time_frame>Up to approximately 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the immune response to neoantigens encoded by GRT-C901 and GRT-R902</measure>
    <time_frame>Baseline to end of treatment (up to approximately 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in Phase 1 using RECIST v1.1</measure>
    <time_frame>Initiation of study treatment until disease progression (up to approximately 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) using RECIST v1.1</measure>
    <time_frame>Initiation of study treatment until disease progression (up to approximately 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (using RECIST v1.1)</measure>
    <time_frame>Initiation of study treatment until disease progression (up to approximately 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients for whom vaccine is successfully manufactured and timeframe for vaccine manufacturing</measure>
    <time_frame>Study enrollment to initiation of study treatment (up to approximately 6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gastroesophageal Adenocarcinoma</condition>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GRT-C901&#xD;
GRT-R902&#xD;
nivolumab&#xD;
ipilimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GRT-C901&#xD;
GRT-R902&#xD;
nivolumab&#xD;
ipilimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GRT-C901</intervention_name>
    <description>a patient-specific neoantigen cancer vaccine prime</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2 Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GRT-R902</intervention_name>
    <description>a patient-specific neoantigen cancer vaccine boost</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2 Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>anti-PD-1 monoclonal antibody</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2 Cohorts</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
    <description>anti-CTLA-4 monoclonal antibody</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2 Cohorts</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide a signed and dated informed consent form prior to initiation of study-specific&#xD;
             procedures.&#xD;
&#xD;
          -  Patients with the indicated advanced or metastatic solid tumor as follows:&#xD;
&#xD;
               1. NSCLC who are planned for or have received no more than 1 cycle of systemic&#xD;
                  treatment with cytotoxic, platinum-based chemotherapy (note: patients who have&#xD;
                  received anti-PD-(L)1 monotherapy are eligible)&#xD;
&#xD;
               2. GEA who are planned for or have received no more than 1 cycle of systemic&#xD;
                  treatment with cytotoxic, platinum-based chemotherapy&#xD;
&#xD;
               3. mUC who are planned for or have received no more than 1 cycle of systemic&#xD;
                  treatment with cytotoxic, platinum-based chemotherapy&#xD;
&#xD;
               4. CRC-MSS who are receiving first line systemic therapy or who are planned for or&#xD;
                  have received no more than 1 cycle of second line systemic therapy including a&#xD;
                  fluoropyrimidine and oxaliplatin or irinotecan&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  ECOG Performance Status 0 or 1&#xD;
&#xD;
          -  Lesion amenable to biopsy&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1&#xD;
&#xD;
          -  Have adequate organ function, as measured by laboratory values (criteria listed in&#xD;
             protocol)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumors with genetic characteristics as follows:&#xD;
&#xD;
               1. For NSCLC, patients with a known genetic driver alteration in EGFR, ALK, ROS1,&#xD;
                  RET, or TRK&#xD;
&#xD;
               2. For CRC and GEA, patients with known MSI-high disease based on institutional&#xD;
                  standard&#xD;
&#xD;
               3. For CRC, patients with a known BRAF V600E mutation or patients with peritoneal&#xD;
                  carcinomatosis and for GEA, patients with peritoneal carcinomatosis as their only&#xD;
                  evidence of disease&#xD;
&#xD;
          -  Patients with known central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis&#xD;
&#xD;
          -  Known exposure to chimpanzee adenovirus or any history of anaphylaxis in reaction to a&#xD;
             vaccination or allergy or hypersensitivity to study drug components&#xD;
&#xD;
          -  Bleeding disorder (eg., factor deficiency, coagulopathy) or history of significant&#xD;
             bruising or bleeding following IM injections or blood draws&#xD;
&#xD;
        Complete inclusion and exclusion criteria are listed in the clinical study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoantigen cancer vaccine</keyword>
  <keyword>personalized neoantigen cancer vaccine</keyword>
  <keyword>GRT-C901</keyword>
  <keyword>GRT-R902</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>nivolumab</keyword>
  <keyword>ipilimumab</keyword>
  <keyword>PD-1</keyword>
  <keyword>CTLA-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

